| Literature DB >> 16376542 |
Cas Smits1, Suzanne J Swen, S Theo Goverts, Annette C Moll, Saskia M Imhof, Antoinette Y N Schouten-van Meeteren.
Abstract
Children with retinoblastoma have increasingly been treated with carboplatin in the past decade. Ototoxicity is a known, possible, side-effect of carboplatin. Since retinoblastoma patients are very young and frequently have impaired vision, the evaluation of hearing loss is very important. The hearing status of 25 children with retinoblastoma treated with carboplatin (median cumulative dose 2,240 mg/m(2)) was evaluated in detail. Median age at first carboplatin administration was 7 months. The evaluation of hearing loss was performed by an age-appropriate measurement protocol consisting of tympanometry, otoacoustic emission measurements, auditory brainstem responses and (high-frequency) visual reinforcement audiometry (VRA) or play-audiometry. The median follow-up time after last carboplatin dose was 25 months (range 1-94 months). In none of the children was hearing loss detected after carboplatin administration. A measurement protocol that includes tympanometry, distortion product otoacoustic emission measurements and high-frequency VRA is recommended for young children receiving carboplatin or other ototoxic drugs.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16376542 DOI： 10.1016/j.ejca.2005.11.004
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162